Neuroendocrine Tumor Drug Market Report

China Neuroendocrine Tumor Drug Industry Market Research Report 2023-2029

  • POSTDATE：Oct 06, 2023
  • PAGES：207
  • REPORT CODE：GMM1832804
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Neuroendocrine Tumor Drug industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Jiangsu Hengrui Medicine Co, Ltd

    • Millennium Pharmaceuticals, Inc

    • Karyopharm Therapeutics, Inc

    • Foresee Pharmaceuticals, LLC

    • INVENT Pharmaceuticals, Inc

    • MolMed SpA

    • OctreoPharm Sciences GmbH

    • Lexicon Pharmaceuticals, Inc

    • Midatech Pharma Plc

    • Northwest Biotherapeutics, Inc

    • Ipsen SA

    • Intezyne, Inc

    • Eisai

    • Hutchison MediPharma Limited

    By Type:

    • Somatostatin receptor antagonists

    • mTOR protein inhibitors

    • Somatostatin receptor agonists

    • Others

    • Tyrosine kinase 3 inhibitors

    • Growth hormone releasing factor antagonists

    By Application:

    • Others

    • Clinic

    • Hospital

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Neuroendocrine Tumor Drug Market Overview 2018-2029

    • 1.1 China Neuroendocrine Tumor Drug Industry Development Overview

    • 1.2 China Neuroendocrine Tumor Drug Industry Development History

    • 1.3 China Neuroendocrine Tumor Drug Industry Market Size (2018-2029)

    • 1.4 China Neuroendocrine Tumor Drug Market Analysis by Type from Production Side

      • 1.4.1 China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Somatostatin receptor antagonists (2018-2029)

      • 1.4.2 China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of mTOR protein inhibitors (2018-2029)

      • 1.4.3 China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Somatostatin receptor agonists (2018-2029)

      • 1.4.4 China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Others (2018-2029)

      • 1.4.5 China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Tyrosine kinase 3 inhibitors (2018-2029)

      • 1.4.6 China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Growth hormone releasing factor antagonists (2018-2029)

    • 1.5 China Neuroendocrine Tumor Drug Market Analysis by Application from Consumption End

      • 1.5.1 China Neuroendocrine Tumor Drug Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

      • 1.5.2 China Neuroendocrine Tumor Drug Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)

      • 1.5.3 China Neuroendocrine Tumor Drug Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)

    • 1.6 China Neuroendocrine Tumor Drug Market Analysis by Region

      • 1.6.1 North China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

    Chapter 2 China Neuroendocrine Tumor Drug Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Neuroendocrine Tumor Drug Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Neuroendocrine Tumor Drug Market Status and Competition Analysis in 2023

      • 2.2.3 China Neuroendocrine Tumor Drug Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Neuroendocrine Tumor Drug Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Neuroendocrine Tumor Drug Industry Development

    Chapter 3 Neuroendocrine Tumor DrugIndustry Chain Analysis

    • 3.1 Neuroendocrine Tumor Drug Industry Chain

    • 3.2 Neuroendocrine Tumor Drug Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Neuroendocrine Tumor Drug Market

    • 3.3 Neuroendocrine Tumor Drug Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Neuroendocrine Tumor Drug Market

    Chapter 4 China Neuroendocrine Tumor Drug Market, by Type

    • 4.1 China Neuroendocrine Tumor Drug Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Neuroendocrine Tumor Drug Total Production Volume and Growth Rate from Production Side

    • 4.5 China Neuroendocrine Tumor Drug Production Volume and Growth Rate, by Type

      • 4.5.1 China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Somatostatin receptor antagonists

      • 4.5.2 China Neuroendocrine Tumor Drug Production Volume and Growth Rate of mTOR protein inhibitors

      • 4.5.3 China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Somatostatin receptor agonists

      • 4.5.4 China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Others

      • 4.5.5 China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Tyrosine kinase 3 inhibitors

      • 4.5.6 China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Growth hormone releasing factor antagonists

    Chapter 5 China Neuroendocrine Tumor Drug Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Neuroendocrine Tumor Drug Total Market Size and Growth Rate from Consumption End

    • 5.5 China Neuroendocrine Tumor Drug Market Size and Growth Rate, by Application

      • 5.5.1 China Neuroendocrine Tumor Drug Market Size and Growth Rate of Others

      • 5.5.2 China Neuroendocrine Tumor Drug Market Size and Growth Rate of Clinic

      • 5.5.3 China Neuroendocrine Tumor Drug Market Size and Growth Rate of Hospital

    Chapter 6 China Neuroendocrine Tumor Drug Market, by Region

    • 6.1 China Neuroendocrine Tumor Drug Production Volume and Production Value, by Region

    • 6.2 China Neuroendocrine Tumor Drug Sales Volume and Sales Value, by Region

    Chapter 7 North China Neuroendocrine Tumor Drug Market Analysis

    • 7.1 North China Neuroendocrine Tumor Drug Market, by Type

    • 7.2 North China Neuroendocrine Tumor Drug Market, by Application

    Chapter 8 Central China Neuroendocrine Tumor Drug Market Analysis

    • 8.1 Central China Neuroendocrine Tumor Drug Market, by Type

    • 8.2 Central China Neuroendocrine Tumor Drug Market, by Application

    Chapter 9 South China Neuroendocrine Tumor Drug Market Analysis

    • 9.1 South China Neuroendocrine Tumor Drug Market, by Type

    • 9.2 South China Neuroendocrine Tumor Drug Market, by Application

    Chapter 10 East China Neuroendocrine Tumor Drug Market Analysis

    • 10.1 East China Neuroendocrine Tumor Drug Market, by Type

    • 10.2 East China Neuroendocrine Tumor Drug Market, by Application

    Chapter 11 Northeast China Neuroendocrine Tumor Drug Market Analysis

    • 11.1 Northeast China Neuroendocrine Tumor Drug Market, by Type

    • 11.2 Northeast China Neuroendocrine Tumor Drug Market, by Application

    Chapter 12 Southwest China Neuroendocrine Tumor Drug Market Analysis

    • 12.1 Southwest China Neuroendocrine Tumor Drug Market, by Type

    • 12.2 Southwest China Neuroendocrine Tumor Drug Market, by Application

    Chapter 13 Northwest China Neuroendocrine Tumor Drug Market Analysis

    • 13.1 Northwest China Neuroendocrine Tumor Drug Market, by Type

    • 13.2 Northwest China Neuroendocrine Tumor Drug Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Jiangsu Hengrui Medicine Co, Ltd

        • 14.1.1 Jiangsu Hengrui Medicine Co, Ltd Company Profile

        • 14.1.2 Jiangsu Hengrui Medicine Co, Ltd Neuroendocrine Tumor Drug Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Millennium Pharmaceuticals, Inc

        • 14.2.1 Millennium Pharmaceuticals, Inc Company Profile

        • 14.2.2 Millennium Pharmaceuticals, Inc Neuroendocrine Tumor Drug Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Karyopharm Therapeutics, Inc

        • 14.3.1 Karyopharm Therapeutics, Inc Company Profile

        • 14.3.2 Karyopharm Therapeutics, Inc Neuroendocrine Tumor Drug Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Foresee Pharmaceuticals, LLC

        • 14.4.1 Foresee Pharmaceuticals, LLC Company Profile

        • 14.4.2 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 INVENT Pharmaceuticals, Inc

        • 14.5.1 INVENT Pharmaceuticals, Inc Company Profile

        • 14.5.2 INVENT Pharmaceuticals, Inc Neuroendocrine Tumor Drug Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 MolMed SpA

        • 14.6.1 MolMed SpA Company Profile

        • 14.6.2 MolMed SpA Neuroendocrine Tumor Drug Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 OctreoPharm Sciences GmbH

        • 14.7.1 OctreoPharm Sciences GmbH Company Profile

        • 14.7.2 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Lexicon Pharmaceuticals, Inc

        • 14.8.1 Lexicon Pharmaceuticals, Inc Company Profile

        • 14.8.2 Lexicon Pharmaceuticals, Inc Neuroendocrine Tumor Drug Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Midatech Pharma Plc

        • 14.9.1 Midatech Pharma Plc Company Profile

        • 14.9.2 Midatech Pharma Plc Neuroendocrine Tumor Drug Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 Northwest Biotherapeutics, Inc

        • 14.10.1 Northwest Biotherapeutics, Inc Company Profile

        • 14.10.2 Northwest Biotherapeutics, Inc Neuroendocrine Tumor Drug Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 Ipsen SA

        • 14.11.1 Ipsen SA Company Profile

        • 14.11.2 Ipsen SA Neuroendocrine Tumor Drug Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Intezyne, Inc

        • 14.12.1 Intezyne, Inc Company Profile

        • 14.12.2 Intezyne, Inc Neuroendocrine Tumor Drug Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 Eisai

        • 14.13.1 Eisai Company Profile

        • 14.13.2 Eisai Neuroendocrine Tumor Drug Market Performance

        • 14.13.3 Product&Service Introduction

      • 14.14 Hutchison MediPharma Limited

        • 14.14.1 Hutchison MediPharma Limited Company Profile

        • 14.14.2 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Market Performance

        • 14.14.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Neuroendocrine Tumor Drug Industry Research Conclusions

    • 15.2 Neuroendocrine Tumor Drug Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Neuroendocrine Tumor Drug Industry Market Size (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Somatostatin receptor antagonists (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of mTOR protein inhibitors (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Somatostatin receptor agonists (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Others (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Tyrosine kinase 3 inhibitors (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Production Volume, Production Value and Growth Rate of Growth hormone releasing factor antagonists (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)

    • Figure China Neuroendocrine Tumor Drug Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)

    • Figure North China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

    • Figure Central China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

    • Figure South China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

    • Figure East China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Neuroendocrine Tumor Drug Market Size and Growth Rate from 2018-2029

    • Figure Neuroendocrine Tumor Drug Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Neuroendocrine Tumor Drug Market Share by Type in 2018

    • Figure China Neuroendocrine Tumor Drug Market Share by Type in 2023

    • Figure China Neuroendocrine Tumor Drug Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Somatostatin receptor antagonists (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Production Volume and Growth Rate of mTOR protein inhibitors (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Somatostatin receptor agonists (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Others (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Tyrosine kinase 3 inhibitors (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Production Volume and Growth Rate of Growth hormone releasing factor antagonists (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Market Share by Application in 2018

    • Figure China Neuroendocrine Tumor Drug Market Share by Application in 2023

    • Figure China Neuroendocrine Tumor Drug Total Market Size and Growth Rate from Consumption End

    • Figure China Neuroendocrine Tumor Drug Market Size and Growth Rate of Others (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Market Size and Growth Rate of Clinic (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Market Size and Growth Rate of Hospital (2018-2023)

    • Table China Neuroendocrine Tumor Drug Production Volume by Region (2018-2023)

    • Table China Neuroendocrine Tumor Drug Production Volume Share by Region (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Production Volume Share by Region (2018-2023)

    • Table China Neuroendocrine Tumor Drug Production Value by Region (2018-2023)

    • Table China Neuroendocrine Tumor Drug Production Value Share by Region (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Production Value Share by Region (2018-2023)

    • Table China Neuroendocrine Tumor Drug Sales Volume by Region (2018-2023)

    • Table China Neuroendocrine Tumor Drug Sales Volume Share by Region (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Sales Volume Share by Region (2018-2023)

    • Table China Neuroendocrine Tumor Drug Sales Value by Region (2018-2023)

    • Table China Neuroendocrine Tumor Drug Sales Value Share by Region (2018-2023)

    • Figure China Neuroendocrine Tumor Drug Sales Value Share by Region (2018-2023)

    • Table North China Neuroendocrine Tumor Drug Production Volume by Type (2018-2023)

    • Table North China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Figure North China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Table North China Neuroendocrine Tumor Drug Sales Volume by Application (2018-2023)

    • Table North China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Figure North China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Table Central China Neuroendocrine Tumor Drug Production Volume by Type (2018-2023)

    • Table Central China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Figure Central China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Table Central China Neuroendocrine Tumor Drug Sales Volume by Application (2018-2023)

    • Table Central China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Figure Central China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Table South China Neuroendocrine Tumor Drug Production Volume by Type (2018-2023)

    • Table South China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Figure South China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Table South China Neuroendocrine Tumor Drug Sales Volume by Application (2018-2023)

    • Table South China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Figure South China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Table East China Neuroendocrine Tumor Drug Production Volume by Type (2018-2023)

    • Table East China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Figure East China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Table East China Neuroendocrine Tumor Drug Sales Volume by Application (2018-2023)

    • Table East China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Figure East China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Table Northeast China Neuroendocrine Tumor Drug Production Volume by Type (2018-2023)

    • Table Northeast China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Figure Northeast China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Table Northeast China Neuroendocrine Tumor Drug Sales Volume by Application (2018-2023)

    • Table Northeast China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Table Southwest China Neuroendocrine Tumor Drug Production Volume by Type (2018-2023)

    • Table Southwest China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Figure Southwest China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Table Southwest China Neuroendocrine Tumor Drug Sales Volume by Application (2018-2023)

    • Table Southwest China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Table Northwest China Neuroendocrine Tumor Drug Production Volume by Type (2018-2023)

    • Table Northwest China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Figure Northwest China Neuroendocrine Tumor Drug Production Volume Share by Type (2018-2023)

    • Table Northwest China Neuroendocrine Tumor Drug Sales Volume by Application (2018-2023)

    • Table Northwest China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Neuroendocrine Tumor Drug Sales Volume Share by Application (2018-2023)

    • Table Jiangsu Hengrui Medicine Co, Ltd Company Profile

    • Table Jiangsu Hengrui Medicine Co, Ltd Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Millennium Pharmaceuticals, Inc Company Profile

    • Table Millennium Pharmaceuticals, Inc Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Karyopharm Therapeutics, Inc Company Profile

    • Table Karyopharm Therapeutics, Inc Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Foresee Pharmaceuticals, LLC Company Profile

    • Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table INVENT Pharmaceuticals, Inc Company Profile

    • Table INVENT Pharmaceuticals, Inc Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table MolMed SpA Company Profile

    • Table MolMed SpA Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table OctreoPharm Sciences GmbH Company Profile

    • Table OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Lexicon Pharmaceuticals, Inc Company Profile

    • Table Lexicon Pharmaceuticals, Inc Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Midatech Pharma Plc Company Profile

    • Table Midatech Pharma Plc Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Northwest Biotherapeutics, Inc Company Profile

    • Table Northwest Biotherapeutics, Inc Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Ipsen SA Company Profile

    • Table Ipsen SA Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Intezyne, Inc Company Profile

    • Table Intezyne, Inc Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Eisai Company Profile

    • Table Eisai Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)

    • Table Hutchison MediPharma Limited Company Profile

    • Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US